Katarzyna Małaczyńska-Rajpold

Dr. Katarzyna Małaczyńska-Rajpold

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
Dominik LinzDominik Linz
Dominik Linz
JAJason G Andrade
Jason G Andrade
Elena ArbeloElena Arbelo
Elena Arbelo
Giuseppe BorianiGiuseppe Boriani
Giuseppe Boriani
GBGuenter Breithardt
Guenter Breithardt
PKPaulus Kirchhof
Paulus Kirchhof
Aims: Recent trial data demonstrate beneficial effects of active rhythm management in patients with atrial fibrillation (AF) and support the concept that a low arrhythmia burden is associated with a low risk of AF-related complications. The aim of this document is to summarize the key outcomes of the 9th AFNET/EHRA Consensus Conference of the Atrial Fibrillation NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Methods and results: Eighty-three international experts met in Münster for 2 days in September 2023. Key findings are as follows: (i) Active rhythm management should be part of the default initial treatment for all suitable patients with AF. (ii) Patients with device-detected AF have a low burden of AF and a low risk of stroke. Anticoagulation prevents some strokes and also increases major but non-lethal bleeding. (iii) More research is needed to improve stroke risk prediction in patients with AF, especially in those with a low AF burden. Biomolecules, genetics, and imaging can support this. (iv) The presence of AF should trigger systematic workup and comprehensive treatment of concomitant cardiovascular conditions. (v) Machine learning algorithms have been used to improve detection or likely development of AF. Cooperation between clinicians and data scientists is needed to leverage the potential of data science applications for patients with AF. Conclusions: Patients with AF and a low arrhythmia burden have a lower risk of stroke and other cardiovascular events than those with a high arrhythmia burden. Combining active rhythm control, anticoagulation, rate control, and therapy of concomitant cardiovascular conditions can improve the lives of patients with AF.

1 July 2025 in EP Europace
Verified
Journal Article
Open access
MFMichal Miroslaw Farkowski
Michal Miroslaw Farkowski
USUniv.-Prof. Priv.-Doz. Dr.med.univ. Daniel Scherr
Univ.-Prof. Priv.-Doz. Dr.med.univ. Daniel Scherr
Giuseppe BorianiGiuseppe Boriani
Giuseppe Boriani
DKDenis Kazakiewicz
Denis Kazakiewicz
Moti HaimMoti Haim
Moti Haim
ECEsc-Ehra Atlas On Heart Rhythm Disorders Contributors
Esc-Ehra Atlas On Heart Rhythm Disorders Contributors
The ESC-EHRA Atlas on Heart Rhythm Disorders was developed to comprehensively map arrhythmia care across the European Society of Cardiology (ESC) member countries. A survey of National Cardiac Societies, Working Groups, and other EHRA partners in ESC member countries was conducted to gather data from 2023 or the most recently available year on arrhythmia care organization and delivery. In total, 51 ESC member countries actively participated in the study, with a survey completeness rate of 91%. The median number of hospitals performing EP or CIED procedures was 3.3 per million people. The annual median numbers of ablation procedures for heart rhythm disorders, atrial fibrillation, and supraventricular tachycardia per million people were 432, 151, and 136, respectively. The annual median numbers of pacemakers, implantable cardioverter-defibrillators (ICD), and cardiac resynchronization therapy cardioverter-defibrillator (CRT-D) implantations per million people were 739, 195, and 54, respectively. The median number of hospitals performing remote monitoring of CIEDs per million people was 0.5, though this service was unavailable in 15 countries. Two main universal issues emerged among the obstacles to guideline implementation: a lack of heart rhythm allied professionals and general dissatisfaction with the country’s reimbursement system. The first edition of the ESC-EHRA Atlas presents up-to-date information on arrhythmia care organization and delivery among ESC member countries and highlights significant discrepancies in patients’ access to ESC-guideline-recommended therapies.

30 August 2022 in EP Europace
Verified
Journal Article
Open access
PDF file
Giuseppe BorianiGiuseppe Boriani
Giuseppe Boriani
ESEmma Svennberg
Emma Svennberg
FGFederico Guerra
Federico Guerra
Dominik LinzDominik Linz
Dominik Linz
RCRuben Casado-Arroyo
Ruben Casado-Arroyo
CLChristophe Leclercq
Christophe Leclercq
Since digital devices are increasingly used in cardiology for assessing cardiac rhythm and detecting arrhythmias, especially atrial fibrillation (AF), our aim was to evaluate the expectations and opinions of healthcare professionals in Europe on reimbursement policies for the use of digital devices (including wearables) in AF and other arrhythmias. An anonymous survey was proposed through announcements on the European Heart Rhythm Association website, social media channels, and mail newsletter. Two hundred and seventeen healthcare professionals participated in the survey: 32.7%, reported regular use of digital devices, 45.2% reported that they sometimes use these tools, 18.6% that they do not use but would like to. Only a minority (3.5%) reported a lack of trust in digital devices. The survey highlighted a general propensity to provide medical consultation for suspected AF or other arrhythmias detected by a consumer-initiated use of digital devices, even if time constraints and reimbursement availability emerged as important elements. More than 85% of respondents agreed that reimbursement should be applied for clinical use of digital devices, also in different settings such as post-stroke, post-cardioversion, post-ablation, and in patients with palpitations or syncope. Finally, 73.6% of respondents confirmed a lack of reimbursement fees in their country for physicians’ consultations (tracings interpretation) related to digital devices. Digital devices, including wearables, are increasingly and widely used for assessing cardiac rhythm and detecting AF, but a definition of reimbursement policies for physicians’ consultations is needed.

4 August 2025 in EP Europace
Verified
Journal Article
Open access
VTVassil Traykov
Vassil Traykov
HPHelmut Purerfellner
Helmut Purerfellner
HBHaran Burri
Haran Burri
CFCsaba Laszlo Foldesi
Csaba Laszlo Foldesi
USUniv.-Prof. Priv.-Doz. Dr.med.univ. Daniel Scherr
Univ.-Prof. Priv.-Doz. Dr.med.univ. Daniel Scherr
JMJosé L Merino
José L Merino
The 2024 European Heart Rhythm Association (EHRA) Summit in Warsaw focused on the digital transformation of arrhythmia management, convening over 130 stakeholders from academia, industry, and policy. This review summarises the current state (in 2025) and future directions of digital health in arrhythmia care, including remote monitoring (RM) of cardiac implantable electronic devices (CIEDs), mobile health (mHealth), artificial intelligence (AI), and integration into the European Health Data Space (EHDS). RM has become central to CIED follow-up, improving outcomes and reducing healthcare use. However, challenges in reimbursement, workforce adaptation, and data interoperability persist. The absence of standardised data exchange between device vendors and healthcare systems has led to initiatives like the World Forum on CIED follow-up to develop interoperability standards. mHealth tools, including apps and wearable devices, offer accurate arrhythmia detection but face regulatory, digital literacy, and privacy barriers. The EHDS aims to enable cross-border data sharing for personalised care and real-world research, though implementation must address ethical, legal, and infrastructural issues. AI shows promise in prediction, monitoring, and data integration, but lacks standardised, transparent validation. The ESC-EHRA Atlas in Heart Rhythm Disorders supports structured data collection to harmonize and benchmark care across Europe. Overall, digital innovations, if coupled with regulatory alignment, interoperability standards, and equitable access, have the potential to shift arrhythmia management toward a more predictive, personalized, and efficient model of care.

1 May 2016 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
KMKatarzyna Małaczyńska-Rajpold
Katarzyna Małaczyńska-Rajpold
AKAnna Komosa
Anna Komosa
KBKrzysztof Błaszyk
Krzysztof Błaszyk
AAAleksander Araszkiewicz
Aleksander Araszkiewicz
MJMagdalena Janus
Magdalena Janus
TMTatiana Mularek-Kubzdela
Tatiana Mularek-Kubzdela

16 August 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
IZIvan Zeljković
Ivan Zeljković
AGAnaïs Gauthey
Anaïs Gauthey
MMMartin Manninger
Martin Manninger
KMKatarzyna Małaczyńska-Rajpold
Katarzyna Małaczyńska-Rajpold
JTJacob Tfelt-Hansen
Jacob Tfelt-Hansen
GCGiulio Conte
Giulio Conte
Aims: Indications and clinical impact of genetic testing for cardiac diseases have increased significantly over the past years. The aim of this physician-based European Heart Rhythm Association (EHRA) survey was to assess current clinical practice and access to genetic testing for cardiac diseases across European Society of Cardiology countries and to evaluate adherence to the 2022 EHRA/HRS/APHRS/LAHRS Expert Consensus Statement on genetic testing. Methods and results: An online questionnaire composed of 28 questions was submitted to the EHRA Research Network and European Reference Network GUARD-Heart healthcare partners and promoted via dedicated social media channels. There were 357 respondents from 69 countries, 40% working in a hospital setting with a cardiac genetic service and/or a dedicated clinic focusing on inherited cardiac diseases and 27% with an onsite genetic laboratory. No genetic testing or low annual rate (<10/year) was declared by 39% of respondents. The majority of respondents (78%) declared issues or limitations to genetic testing access in their clinical practice. The main reasons for not providing or limited access to genetic testing were no availability of dedicated unit or genetic laboratory (35%) or reimbursement issues (25%). The most frequently reported indication for genetic testing was diagnostic purpose (55%). Most respondents (92%) declared offering genetic testing preceded by genetic counselling and 42% regular multidisciplinary evaluations for patients with cardiac genetic diseases. The perceived value of genetic testing in the diagnostic, prognostic, and therapeutic assessment was variable (67, 39, and 29%, respectively) and primarily based on the specific inherited disease. The majority of respondents recommended cascade genetic testing for the first-degree family members in case of pathogenic/likely pathogenic variant in the proband. Conclusion: This survey highlights a significant heterogeneity of genetic testing access and provision and issues attributable to the availability of dedicated unit/genetic laboratory and reimbursement. However, adequate adherence to indications in the current recommendations for genetic testing in patients with cardiac diseases was observed.